Sign In
3 Aug 2016 07:00
Venn Life Sciences Holdings Plc
("Venn" or the "Company")
Contract wins
Venn Life Sciences (AIM: VENN), a growing Contract Research Organisation (CRO) providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that it has signed a new contract worth €2.8m with a European Biotechnology client. The clinical trial is a Phase II study in the area of Immunotherapeutic treatments for Multiple Sclerosis and involves patients in six countries across Europe and commences in October 2016.
Furthermore Venn's Interactive Response Technology ("IRT") department, which centralises the randomisation of patients for Phase I to IV clinical trails and manages the logistics of these studies, has successfully qualified as a service provider to a top ten Pharmaceutical client and has been awarded an initial project involving thirty sites in China. This vendor qualification is a significant milestone for the IRT division and represents an exciting opportunity to grow a global account.
Commenting, Venn CEO, Tony Richardson said: "I am pleased to see the addition of a significant new account for Venn. We are now benefitting from a good balance of repeat business, client referals and new business wins from prospecting. I am particularly pleased with our success in IRT. Coming through the vendor qualification and audit process with "big-pharma" represents a significant step for our organisation and high quality execution of this initial project should result in a rich vein of new business."
Enquiries:
Venn Life Sciences Holdings Plc | www.vennlifesciences.com | |
Tony Richardson, Chief Executive Officer | Tel: +353 154 99 341 | |
Jonathan Hartshorn, Chief Financial Officer | Tel: +353 153 93 269 | |
Aoife O Farrell, Marketing Manager | Tel: +353 153 93 269 | |
|
| |
Davy (Nominated Adviser, ESM Adviser and Joint Broker) | Tel: +353 1 679 6363 | |
Fergal Meegan / Matthew DeVere White (Corporate Finance) |
| |
Paul Burke (Corporate Broking) |
| |
|
| |
Hybridan LLP (Joint-Broker) |
| |
Claire Louise Noyce | Tel: 020 3764 2341 | |
|
| |
Walbrook PR Ltd | Tel: 020 7933 8787 or venn@walbrookpr.com | |
Paul McManus | Mob: 07980 541 893 | |
Lianne Cawthorne | Mob: 07584 391 303 | |
About Venn Life Sciences Limited: Venn Life Sciences is a Contract Research Organisation providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn Life Sciences specialises in rapid deployment and management of multisite projects, across all phases. Venn Life Sciences also has an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.
For more information about the Company, please visit: www.vennlifesciences.com
Follow the stocks
